Lv1
38 积分 2025-10-19 加入
Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer
1天前
已完结
Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer
1天前
已完结
Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity
2天前
已完结
TOP2A, BUB1B, CENPF, KIF15 and MELK: Key senescence-related genes linked to prognosis and immune infiltration in lung adenocarcinoma
2天前
已完结
Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2- breast cancer: A phase 1b/2 trial
8个月前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
